By , (Reuters) - The United States is preparing to issue guidance on reducing “unnecessary” testing for COVID-19 as it works to cut turnaround times for tests, a senior U.S. health official said on Thursday.Details of the guidance are still being hammered out but it would be aimed partly at discouraging COVID-19 patients who have completed home quarantine from getting retested before returning to work or school, said Brett Giroir, assistant secretary for health at the U.S. Department of Health and Human Services.Speaking on a call with reporters, he said such unnecessary tests were...…By , (Reuters) - The United States is preparing to issue guidance on reducing “unnecessary” testing for COVID-19 as it works to cut turnaround times for tests, a senior U.S. health official said on Thursday.Details of the guidance are still being hammered out but it would be aimed partly at discouraging COVID-19 patients who have completed home quarantine from getting retested before returning to work or school, said Brett Giroir, assistant secretary for health at the U.S. Department of Health and Human Services.Speaking on a call with reporters, he said such unnecessary tests were...WW…

By , (Reuters) - Novavax Inc’s COVID-19 vaccine was 96% effective in preventing cases caused by the original version of the coronavirus in a late-stage trial conducted in the United Kingdom, the company said on Thursday, moving it a step closer to regulatory approval.There were no cases of severe illness or deaths among those who got the vaccine, the company said, in a sign that it could stop the worse effects of new variants that have cropped up.The vaccine was 86% effective in protecting against the more contagious virus variant first discovered and now prevalent in the United Kingdom,...…By , (Reuters) - Novavax Inc’s COVID-19 vaccine was 96% effective in preventing cases caused by the original version of the coronavirus in a late-stage trial conducted in the United Kingdom, the company said on Thursday, moving it a step closer to regulatory approval.There were no cases of severe illness or deaths among those who got the vaccine, the company said, in a sign that it could stop the worse effects of new variants that have cropped up.The vaccine was 86% effective in protecting against the more contagious virus variant first discovered and now prevalent in the United Kingdom,...WW…

By , (Reuters) - Novavax Inc’s COVID-19 vaccine was 96% effective in preventing cases caused by the original version of the coronavirus in a late-stage trial conducted in the United Kingdom, the company said on Thursday, moving it a step closer to regulatory approval.There were no cases of severe illness or deaths among those who got the vaccine, the company said, in a sign that it could stop the worse effects of new variants that have cropped up.The vaccine was 86% effective in protecting against the more contagious virus variant first discovered and now prevalent in the United Kingdom,...…By , (Reuters) - Novavax Inc’s COVID-19 vaccine was 96% effective in preventing cases caused by the original version of the coronavirus in a late-stage trial conducted in the United Kingdom, the company said on Thursday, moving it a step closer to regulatory approval.There were no cases of severe illness or deaths among those who got the vaccine, the company said, in a sign that it could stop the worse effects of new variants that have cropped up.The vaccine was 86% effective in protecting against the more contagious virus variant first discovered and now prevalent in the United Kingdom,...WW…